Skip to main content
. 2022 Jan 20;12:748473. doi: 10.3389/fneur.2021.748473

Figure 1.

Figure 1

The prevalence of PSF in the acute phase and at 6, 12, and 24 months of follow-up in the PSD subgroup. Compared with untreated patients, the incidence of PSF in patients treated with SSRIs was higher at baseline. The incidence rate of patients in the treated group decreased over time (red line). The incidence rate of the untreated group increased over the first 6 months and then decreased (blue line). PSD, poststroke depression; PSF, poststroke fatigue.